PlainRecalls
FDA Drug Moderate Class II Terminated

EXPAREL, Bupivicaine Liposome Injectable Suspension, 1.3%, 266 mg/20 mL (13 mg/mL), Sterile, 20 mL vial, Rx only, Manufactured by: Pacira Pharmaceuticals, Inc. San Diego, CA 92121. NDC: 65250-266-20,

Reported: December 11, 2019 Initiated: November 21, 2019 #D-0621-2020

Product Description

EXPAREL, Bupivicaine Liposome Injectable Suspension, 1.3%, 266 mg/20 mL (13 mg/mL), Sterile, 20 mL vial, Rx only, Manufactured by: Pacira Pharmaceuticals, Inc. San Diego, CA 92121. NDC: 65250-266-20,

Reason for Recall

Sub Potent Drug: Out of Specification (OOS)

Details

Units Affected
910 20 mL vials
Distribution
Distributed Nationwide in the USA
Location
San Diego, CA

Frequently Asked Questions

What product was recalled?
EXPAREL, Bupivicaine Liposome Injectable Suspension, 1.3%, 266 mg/20 mL (13 mg/mL), Sterile, 20 mL vial, Rx only, Manufactured by: Pacira Pharmaceuticals, Inc. San Diego, CA 92121. NDC: 65250-266-20,. Recalled by Pacira Pharmaceuticals, Inc.. Units affected: 910 20 mL vials.
Why was this product recalled?
Sub Potent Drug: Out of Specification (OOS)
Which agency issued this recall?
This recall was issued by the FDA Drug on December 11, 2019. Severity: Moderate. Recall number: D-0621-2020.